[1] It entered the biotechnology space in July 2010 when it purchased a 38.6 per cent stake in Brisbane-based Coridon for A$3 million.
[3] In February 2011, Allied Medical agreed to a reverse takeover deal with BioMD, a listed biotech company.
[3] The takeover was completed in June 2011 resulting in the combined company, Allied Healthcare Group, listing on the Australian Securities Exchange (ASX).
[7] In October 2019, Admedus sold its CardioCel and VascuCel patch business to U.S.-based LeMaitre Vascular.
[10] Admedus retained the right to manufacture CardioCel and VascuCel products at its Malaga facility for LeMaitre over the following three years.